Welcome a new era of therapeutic development in which natural compounds can be leveraged to accelerate the delivery of breakthrough medical solutions.

WE ARE ANDIRA PHARMACEUTICALS

Our mission is to improve patient outcomes by advancing therapy for critical illness.

Andira is a privately held health science firm, leveraging natural compounds to accelerate the delivery of urgently-needed solutions for antibiotic-resistant infections and metastatic cancer.

Andira is home to:

Asset 6

Novel Pharmacotherapeutic Platform

Applying proven innovation to generate a consistent stream of technologies that address highly prevalent medical conditions

Asset 5

Therapeutic and Medical Device Products

Following established regulatory pathways to achieve product approvals

Asset 4

An Industry-Leading Team

A proven track record of pharmaceutical commercialization success through execution of viable scientific, clinical and regulatory strategies

FOCUS AREAS

Therapeutic
Development
Programs

Dermatology

Our novel, Matrix3 triple synergy formula provides faster onset and improved efficacy against drug-resistant bacteria including MRSA and Pseudomonas.

Hospital Acquired Infections

Our Hospital Infections program is advancing an injectable product for Drug-Resistant Enterococcus (“VRE”) – a life-threatening hospital-acquired infection.

Oncology

Andira uses the most translational research techniques available to optimize treatments to address Metastatic Breast Cancer.

COMPANY NEWS AND EVENTS

Latest News